# Edgewood Oncology

> Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class oral small-molecule multi-kinase inhibitor that co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - three master regulators of cancer cell survival and transcription. Founded by veteran biotech executive David N. Cook and emerging from stealth in March 2024 with $20M in Series A financing from Alta Partners, the company is advancing BTX-A51 through Phase 2a trials in relapsed/refractory acute myeloid leukemia and genetically-defined (GATA3-mutant) ER+/HER2- metastatic breast cancer.

- **Founded:** 2023
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** David N. Cook (Founder & Chief Executive Officer), Yinon Ben-Neriah (Scientific Founder (BTX-A51 inventor, Hebrew University of Jerusalem))
- **Team size:** Small (~2 employees per public records; lean clinical-stage operation)
- **Products:** BTX-A51
- **Notable:** Emerged from stealth in March 2024 with $20M Series A from Alta Partners., Acquired worldwide rights to BTX-A51 from Yissum (Hebrew University of Jerusalem) in 2023., Completed Phase 1 first-in-human dose-escalation of BTX-A51 in advanced MDS/AML.

## Products & services

- **BTX-A51** — A first-in-class, oral, small-molecule multi-kinase inhibitor that synergistically co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - master regulators of cancer cell survival and transcriptional control - to promote apoptosis (programmed cell death). In development for relapsed/refractory AML and genetically-defined breast cancer.

## Achievements

- Emerged from stealth in March 2024 with $20M Series A from Alta Partners.
- Acquired worldwide rights to BTX-A51 from Yissum (Hebrew University of Jerusalem) in 2023.
- Completed Phase 1 first-in-human dose-escalation of BTX-A51 in advanced MDS/AML.
- Dosed first patients in a Phase 2a study of BTX-A51 in genetically-defined metastatic breast cancer.
- Reported positive preclinical efficacy data for BTX-A51 in liposarcoma models via an investigator-sponsored study.

## Latest updates

- **2024-03** — Emerged from stealth with $20M Series A financing led by Alta Partners to advance BTX-A51.
- **2024** — Initiated and dosed first patients in Phase 2a study of BTX-A51 in genetically-defined (ER+/HER2-, GATA3-mutant) metastatic breast cancer.
- **2024** — Announced positive preclinical efficacy data for BTX-A51 in liposarcoma models from an investigator-sponsored study.

## Links

- Website: https://edgewoodoncology.com
- LinkedIn: https://www.linkedin.com/company/edgewood-oncology

---

Profile page: https://yespress.io/edgewood-oncology
Published by YesPress — https://yespress.io
Last updated: 2026-06-15